BTIG Research Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX)

BTIG Research started coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report released on Thursday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $40.00 price target on the stock. BTIG Research’s target price would suggest a potential upside of 331.03% from the company’s current price.

Separately, HC Wainwright initiated coverage on shares of Avalo Therapeutics in a research report on Thursday, October 24th. They set a “neutral” rating on the stock.

Avalo Therapeutics Trading Down 1.1 %

Shares of AVTX opened at $9.28 on Thursday. Avalo Therapeutics has a 52 week low of $3.95 and a 52 week high of $34.46. The stock has a fifty day moving average of $11.15 and a 200-day moving average of $10.76.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Affinity Asset Advisors LLC boosted its holdings in Avalo Therapeutics by 350.0% during the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock worth $561,000 after acquiring an additional 35,000 shares during the last quarter. Logos Global Management LP bought a new stake in Avalo Therapeutics during the second quarter worth $6,722,000. Ikarian Capital LLC boosted its position in Avalo Therapeutics by 1,673.0% in the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after purchasing an additional 915,629 shares during the last quarter. Finally, RA Capital Management L.P. bought a new position in Avalo Therapeutics in the 3rd quarter valued at $9,186,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.